Cell Therapeutics running out of cash

Seattle-based Cell Therapeutics is sending out an SOS signal to investors. "We have an immediate need to raise additional capital in the next thirty days in order to meet our operation needs," the company said in SEC documents. Cell Therapeutics also said that it does not have enough money to get through the current quarter. The biotech, which has yet to file its quarterly statement through June 30, stated that it ended the first quarter with $15.3 million in cash and $47.9 million in liabilities. The Seattle Times notes that CTI "subsequently raised a net $40 million in two financings."

- read the story in the Seattle Times

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.